Science
Mechanism of Action
This advanced bioengineered peptide, synonymous with Epidermal Growth Factor (EGF), operates as a direct cellular signal. It selectively binds to specific EGF receptors (EGFRs) present on the surface of skin cells. This specific binding event initiates a complex cascade of intracellular signaling, driving essential cellular processes such as growth, proliferation, and differentiation. Specifically, RH-Oligopeptide-1 stimulates the natural production of critical structural proteins like collagen and elastin, which contributes to improved skin firmness, elasticity, and a reduction in the appearance of fine lines and wrinkles. It actively supports enhanced skin repair by accelerating the regeneration of new skin cells, facilitating wound healing with a reduced propensity for scarring. Additionally, this ingredient helps fortify the skin's natural barrier, reduces inflammatory responses, and improves moisture retention, resulting in a more hydrated and plump skin appearance.
Research
Clinical Evidence
Medium confidenceN/A
Transparency
Dusting Analysis
No data available to suggest this ingredient is commonly dusted or used at ineffective percentages.
The Formula
Formulation
Stability
RH-Oligopeptide-1 is highly sensitive to pH variations, necessitating that the final product's pH is precisely adjusted to a range of 5.0-8.0 prior to its incorporation. It is also susceptible to enzymatic degradation by microorganisms, making stringent avoidance of microbial contamination during processing paramount to preserve its activity.
Safety
Safety Profile
RH-Oligopeptide-1 (sh-oligopeptide-1) is broadly authorized as a cosmetic ingredient, deemed compatible with standard cosmetic formulations and adhering to international regulatory guidelines. It is categorized by CosIng (European Commission) as a 'skin protecting' agent (specifically for Nicotiana Benthamiana rh-Oligopeptide-1) and is not found on the EWG's Restricted or Unacceptable Lists, with no indication of being carcinogenic. However, certain sources articulate concerns regarding 'unknown long-term risks' and argue that 'active EGF' may function more as a potent, unauthorized drug rather than a cosmetic. These sources also highlight a perceived lack of scientific basis for clinical studies on sh-oligopeptide-1, citing unproven preclinical bioactivity.
Your Skin
Skin Compatibility
Our Assessment
Verdict
RH-Oligopeptide-1 presents strong theoretical and reported clinical efficacy for comprehensive skin rejuvenation and repair; however, significant concerns from some scientific sources regarding its classification as an 'unauthorized drug' and unproven preclinical bioactivity necessitate a cautious approach and further long-term safety validation for a precision skincare brand.
Related
Similar Ingredients
Finding similar ingredients…